Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains
-
By
-
Wenxuan Peng
-
Hailian Wu
-
Li Zhang
-
Binyang Zheng
-
Qi Zhang
-
Wenyuan Xin
-
Xiaoyan Yang
-
Kaiye Ying
-
Ru Ma
-
Hongxing Pan
-
Qingwen Zhang
-
Haisheng Wu
-
June 23, 2026
-
Clinical Scorecard: Efficacy of High-Affinity Monoclonal Antibodies Against Resistant Strains of Plague
At a Glance
| Category | Detail |
|---|
| Condition | Plague caused by Yersinia pestis |
| Key Mechanisms | Monoclonal antibodies enhance opsonophagocytosis, block T3SS, and activate complement pathways. |
| Target Population | Individuals at risk of Y. pestis infection, including those exposed to drug-resistant strains. |
| Care Setting | Infectious disease management and research settings. |
Key Highlights
- Monoclonal antibodies Fm3 and Fm25 provide protection against virulent and drug-resistant Y. pestis.
- Fm25 achieved 100% protection at 100 µg against drug-resistant strain S19960127.
- Partial protection (25% survival) was observed with Fm3 at 20 µg.
- No protective efficacy was noted at lower dosages (20 µg and 4 µg).
Guideline-Based Recommendations
Diagnosis
- Diagnosis of plague should be based on clinical presentation and laboratory confirmation.
Management
- Current management includes antibiotics such as streptomycin, tetracyclines, and chloramphenicol.
Monitoring & Follow-up
- Monitor for signs of infection and response to treatment in patients at risk.
Risks
- Rising antibiotic resistance poses significant challenges in plague management.
Patient & Prescribing Data
Patients exposed to Y. pestis, particularly in endemic regions.
Clinical Best Practices
- Implement integrated pest management to control rodent populations.
- Utilize vaccination strategies in high-risk populations.
Related Resources & Content
